Cancer Genetics (CGIX) Sees IPO Price in $11-$13/Share Range
Tweet Send to a Friend
In an amended S-1 filing from Monday morning, Cancer Genetics (Nasdaq: CGIX) disclosed it expects to price 4 million shares of its common stock in the range of $11-$13 per share. The company plans to list on the NASDAQ exchange under the symbol "CGIX."
The offering is being made through Needham & Company and First Analysis Securities.
Cancer Genetics is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The offering is being made through Needham & Company and First Analysis Securities.
Cancer Genetics is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Cancer Genetics to Present at Marcum MicroCap Conference
- GDC Technology (GDCT) Files $75M IPO
- KKR & Co. Might Push for Neiman Marcus, Saks (SKS) Merger
Create E-mail Alert Related Categories
IPOsRelated Entities
Needham & Company, First Analysis, S1
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
